BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 3069285)

  • 1. Therapeutic evaluation of omeprazole.
    Adams MH; Ostrosky JD; Kirkwood CF
    Clin Pharm; 1988 Oct; 7(10):725-45. PubMed ID: 3069285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lansoprazole: a comprehensive review.
    Zimmermann AE; Katona BG
    Pharmacotherapy; 1997; 17(2):308-26. PubMed ID: 9085323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omeprazole: a new approach to gastric acid suppression.
    Buhl K; Clearfield HR
    Am Fam Physician; 1990 Apr; 41(4):1225-7. PubMed ID: 2321497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omeprazole: a comprehensive review.
    Massoomi F; Savage J; Destache CJ
    Pharmacotherapy; 1993; 13(1):46-59. PubMed ID: 8437967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lansoprazole--profile of a new proton pump inhibitor].
    Seifert E
    Leber Magen Darm; 1994 Mar; 24(2):66-8, 71. PubMed ID: 8196467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Lansoprazol ++ : a new proton pump inhibitor].
    Baczek J; Laskowiec G
    Pol Merkur Lekarski; 1998 Jun; 4(24):339-41. PubMed ID: 9771021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of acid pump antagonists (reversible PPIs).
    Wurst W; Hartmann M
    Yale J Biol Med; 1996; 69(3):233-43. PubMed ID: 9165692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
    Huang JQ; Hunt RH
    Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omeprazole: a novel antisecretory agent for the treatment of acid-peptic disorders.
    Lampkin TA; Ouellet D; Hak LJ; Dukes GE
    DICP; 1990 Apr; 24(4):393-402. PubMed ID: 2183494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. pH, healing rate, and symptom relief in patients with GERD.
    Huang JQ; Hunt RH
    Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole.
    Bown RL
    Int J Clin Pract; 2002 Mar; 56(2):132-9. PubMed ID: 11926700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
    Florent C
    Clin Ther; 1993; 15 Suppl B():14-21. PubMed ID: 7911399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dose-response effect of lansoprazole in patients with Zollinger-Ellison syndrome].
    Mignon M; Hochlaf S; Forestier S; Ruszniewski P; Vatier J; Joubert-Collin M
    Gastroenterol Clin Biol; 1994; 18(1):13-6. PubMed ID: 8187984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacology of omeprazole.
    Howden CW
    Clin Pharmacokinet; 1991 Jan; 20(1):38-49. PubMed ID: 2029801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical treatment of peptic ulcers.
    Deveney CW; Deveney KE
    Surg Annu; 1985; 17():219-33. PubMed ID: 3883541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of patients with Zollinger-Ellison syndrome.
    Mignon M; Pospai D; Forestier S; Vatier J; Vallot T
    Clin Ther; 1993; 15 Suppl B():22-31. PubMed ID: 8205592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-steroidal anti-inflammatory drug gastropathy: clinical results with H2 antagonists and proton pump inhibitors.
    Lazzaroni M; Bianchi Porro G
    Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S73-8. PubMed ID: 10379473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of acid-suppressive agents in patients with gastroesophageal reflux disease.
    Schentag JJ; Goss TF
    Am J Hosp Pharm; 1993 Apr; 50(4 Suppl 1):S7-10. PubMed ID: 8097364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases.
    Andersson K; Carlsson E
    Pharmacol Ther; 2005 Dec; 108(3):294-307. PubMed ID: 16000224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of omeprazole, a substituted benzimidazole, on gastrointestinal secretions, serum gastrin, and gastric mucosal blood flow in dogs.
    Konturek SJ; Cieszkowski M; KwiecieĊ„ N; Konturek J; Tasler J; Bilski J
    Gastroenterology; 1984 Jan; 86(1):71-7. PubMed ID: 6689674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.